Skip to content
sellWeak cluster of 2

Weiguo Ye sold $59k of GYRE

Chief Operating Officer at GYRE THERAPEUTICS, INC.. 9,320 shares at an average of $6.38, traded May 18, 2026, filed May 20, 2026.

Warning score
20
Value
$59k
9,320 shares
Holdings after
700,000
-1% from before
From 52-week low
0%
low $6.44, close $6.44
From 52-week high
-44%
high $11.40, as of May 18, 2026

Score components

  • Role
    COO
    +20
  • Trade size
    $59k at market
    +7
  • Share of holdings sold
    Sold 1.3% of holdings
    0
  • Cluster
    2 insiders selling within 14 days
    +8
  • Exercise and sell
    Shares came from an option exercise in the same filing
    -15

What happened after comparable sells

Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.

This signal so far: 1m +3.5%, 3m +18.4%, 6m -.

Price around the trade, and since

From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.

GYREOct 9, 2026 · close 7.04
Since filing May 20, 2026: +16.6%SPY +5.6% · excess +11.0%

Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™

Rows in this filing

Every transaction in Form 4 0001140361-26-022235, as filed. Open on EDGAR

DateTransactionSharesPriceValueHoldings afterFiled
May 18, 2026MOption exercise
Common Stock
+200$0.75$150700,200May 20, 2026
May 18, 2026SOpen-market sale
Common Stock
-200$6.62$1,324700,000May 20, 2026
May 19, 2026MOption exercise
Common Stock
+9,120$0.75$6,840709,120May 20, 2026
May 19, 2026SOpen-market sale
Common Stock
-9,120$6.37$58k700,000May 20, 2026
May 18, 2026MOption exercise
Stock Option (Right to Buy)derivative
-200$0.00$0936,235May 20, 2026
May 19, 2026MOption exercise
Stock Option (Right to Buy)derivative
-9,120$0.00$0927,115May 20, 2026

Related signals

Other insiders at GYRE THERAPEUTICS, INC. and this insider’s other filings.

ScoreCompanyInsiderValueHoldingsFiled
13Weak
GYREsell
GYRE THERAPEUTICS, INC.
Weiguo Ye
Chief Operating Officer
$69k
11,000 shares
-2%
5Weak
GYREsell
GYRE THERAPEUTICS, INC.
Weiguo Ye
Chief Operating Officer
$17k
2,800 shares
-0%
16Weak
GYREsell
GYRE THERAPEUTICS, INC.
Weiguo Ye
Chief Operating Officer
$129k
20,918 shares
-3%
17Weak
GYREsell
GYRE THERAPEUTICS, INC.
Weiguo Ye
Chief Operating Officer
$219k
34,976 shares
-5%
11Weak
GYREsell
GYRE THERAPEUTICS, INC.
Weiguo Ye
Chief Operating Officer
$46k
7,500 shares
-1%
16Weak
GYREsell
GYRE THERAPEUTICS, INC.
Weiguo Ye
Chief Operating Officer
$137k
22,220 shares
-3%
25Weak
GYREsell 2
GYRE THERAPEUTICS, INC.
Weiguo Ye
Chief Operating Officer
$195k
28,680 shares
-4%
22Weak
GYREsell 210b5-1
GYRE THERAPEUTICS, INC.
Ying Luo
Chief Executive Officer
$83k
10,315 shares
-0%
5Weak
GYREsell10b5-1
GYRE THERAPEUTICS, INC.
Songjiang Ma
President
$26k
2,558 shares
-0%
0Weak
GYREsell10b5-1
GYRE THERAPEUTICS, INC.
Songjiang Ma
President
$24k
2,182 shares
-0%

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.